
Jacobo Mintzer, MD, MPA, discussed a wide range of Alzheimer disease related topics, including the use of methylphenidate, reactions to AAIC, and the aducanumab approval.

Jacobo Mintzer, MD, MPA, discussed a wide range of Alzheimer disease related topics, including the use of methylphenidate, reactions to AAIC, and the aducanumab approval.

The assistant professor of pediatrics and neurology at the University of Colorado School of Medicine discussed the importance of headache research in gender minorities.

Peter Crino, MD, and Steven Roberds, PhD, join NeurologyLive to discuss several topics regarding the state of care for tuberous sclerosis complex, and the future of and advances in research.

Here's what is coming soon to NeurologyLive.

Both short and long sleep durations were associated with worse self-reported cognitive function and multiple lifestyle outcomes, suggesting a U-shaped association.

Investigators evaluated the effect of pain on sleep disturbance and vice-versa over time, finding stable differences between patients in sleep and pain.

Discussing the key takeaways for clinicians when it comes to treating this patient population, the assistant professor of pediatrics and neurology at the University of Colorado School of Medicine emphasized the need to improve communication.

Older adults with CI were found to require a significantly higher number of visits during home health care episodes, particularly skilled nursing visits.

The 50% responder rate was 58.3% at 12 months and 50.0% at the last visit, with corresponding seizure freedom rates of 23.2% and 20.5%, respectively.

Neurology News Network for the week ending September 4, 2021.

Two study authors provide commentary on data that suggests that offering clinicians more perspective into the individual patient experience can help inform care for those individuals with DRP.

Craig Martin, CEO, Global Genes, offered his inside perspective on the multistakeholder initiative and the fruits it hopes to bear for patients with rare CNS diseases.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 3, 2021.

Impel’s agent is designed to deliver a lower dose of dihydroergotamine mesylate (DHE) compared with other nasally administered products.

The assistant professor of pediatrics and neurology at the University of Colorado School of Medicine spoke on a recent narrative review investigating headache in gender minorities.

Episode 14 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Nina Browner, MD, of University of North Carolina School of Medicine. [WATCH TIME: 5 minutes]

Investigators concluded that the most sensitive screening tool for OSA in women with IIH was the STOP-BANG questionnaire.

The director of the Banner Alzheimer’s Institute discussed areas of success and those facing challenges for Alzheimer disease clinical trials.

Patients with chronic migraine were advised to reduce cannabis use to aid in reducing medication overuse headache.

Advocacy organization Cure SMA provides insight on the importance of continuing to push for standardized newborn screening and how it can positively impact outcomes in SMA.

Investigators found that strength training improved muscle strength, balance, gait speed, and gross motor function in pediatric and adolescent patients.

The professor of neurology at Emory University School of Medicine spoke on the potential for the new AASM hypersomnolence guideline to educate providers treating patients with sleep disorders.

Davis offered comments on the recent approval of brivaracetam (Birviact; UCB) as a treatment for pediatric patients with partial-onset seizures and its potential for these patients.

The director of the Alzheimer’s Prevention Clinic at Weill Cornell Medicine discussed the topics and ideas that clinicians should look forward to at the 2021 International Congress on the Future of Neurology.

The web-implemented algorithm misclassified and misdiagnosed seizures in only 16.8% of the patients with epilepsy—lower than rates previously reported in the literature.

The global head of Neurodegeneration at Roche/Genentech offered her insights on additional analysis of the DIAN-TU trial of gantenerumab and perspectives on biomarker data.

Investigators concluded that feedback from patients and caregivers should be incorporated as telehealth continues to be integrated into daily clinical care.

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the current understanding of COVID-19 and its associations with cognitive decline and Alzheimer disease.

Internet-based cognitive behavioral therapy for insomnia program engagement was low and did not elicit a change in medication use or health care visits.

Expert clinicians offer their perspectives on the upcoming IFN 2021 Congress, the impact of aducanumab, optic neuritis in NMOSD, cranial neuralgias, and miniature AD brain models.